Fenoglide
NDC Package 52725-495-90
Package Information
Fenoglide is contraindicated in patients with severe renal dysfunction, including those receiving dialysis [see Clinical Pharmacology (12.3).]Fenoglide is contraindicated in patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions (5.1).]Fenoglide is contraindicated in patients with gallbladder disease [see Warnings and Precautions (5.2).]Fenoglide is contraindicated in nursing mothers [see Use in Specific Populations (8.3).]Fenoglide is contraindicated in patients who have a known hypersensitivity to fenofibrate, such as severe skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Marketed by Shore Therapeutics, Inc, this product is identified by NDC 52725-495 and is authorized under FDA application NDA022118.
Identification & Billing
- RxCUI: 749802 - fenofibrate 120 MG Oral Tablet
- RxCUI: 749804 - fenofibrate 40 MG Oral Tablet
- RxCUI: 763250 - Fenoglide 120 MG Oral Tablet
- RxCUI: 763250 - fenofibrate 120 MG Oral Tablet [Fenoglide]
- RxCUI: 763252 - Fenoglide 40 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 52725 - Shore Therapeutics, Inc
- 52725-495 - Fenoglide
- 52725-495-90 - 90 TABLET in 1 BOTTLE, PLASTIC
- 52725-495 - Fenoglide
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (52725-495). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 52725-495-90 identifies a specific commercial package of 90 tablet in 1 bottle, plastic of Fenoglide, labeled by Shore Therapeutics, Inc. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Shore Therapeutics, Inc on November 18, 2010. The current certification is valid through December 31, 2018.
How is this Shore Therapeutics, Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 52725049590. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.